Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 10 | 2024 | 878 | 4.600 |
Why?
|
| Graft vs Host Disease | 4 | 2023 | 365 | 2.400 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2023 | 170 | 1.580 |
Why?
|
| Transplantation, Autologous | 4 | 2021 | 331 | 1.150 |
Why?
|
| Sarcopenia | 1 | 2023 | 13 | 0.920 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2024 | 763 | 0.910 |
Why?
|
| Primary Myelofibrosis | 1 | 2022 | 56 | 0.830 |
Why?
|
| Quality of Life | 2 | 2020 | 1585 | 0.810 |
Why?
|
| Transplantation Conditioning | 2 | 2022 | 373 | 0.750 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2024 | 346 | 0.750 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 98 | 0.720 |
Why?
|
| Hematopoiesis | 1 | 2020 | 163 | 0.710 |
Why?
|
| POEMS Syndrome | 1 | 2018 | 2 | 0.680 |
Why?
|
| Polyneuropathies | 1 | 2018 | 27 | 0.660 |
Why?
|
| Muscle Weakness | 1 | 2018 | 61 | 0.650 |
Why?
|
| Leg | 1 | 2018 | 137 | 0.650 |
Why?
|
| Immunoglobulins | 1 | 2018 | 148 | 0.640 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 166 | 0.620 |
Why?
|
| Telemedicine | 1 | 2020 | 169 | 0.600 |
Why?
|
| Transplantation, Homologous | 3 | 2022 | 996 | 0.520 |
Why?
|
| Pandemics | 1 | 2021 | 740 | 0.500 |
Why?
|
| Mastoiditis | 1 | 2013 | 4 | 0.470 |
Why?
|
| Otitis Externa | 1 | 2013 | 5 | 0.470 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2013 | 13 | 0.470 |
Why?
|
| Abscess | 1 | 2013 | 91 | 0.450 |
Why?
|
| Antigens, CD34 | 2 | 2022 | 158 | 0.420 |
Why?
|
| Diabetes Complications | 1 | 2013 | 207 | 0.410 |
Why?
|
| Humans | 16 | 2024 | 86643 | 0.340 |
Why?
|
| Survival Analysis | 2 | 2022 | 1538 | 0.300 |
Why?
|
| Disease Progression | 2 | 2021 | 1531 | 0.280 |
Why?
|
| Medical Futility | 1 | 2024 | 28 | 0.240 |
Why?
|
| Transplantation, Haploidentical | 1 | 2023 | 27 | 0.240 |
Why?
|
| Nutritional Status | 1 | 2023 | 83 | 0.220 |
Why?
|
| Body Composition | 1 | 2023 | 68 | 0.220 |
Why?
|
| Tissue Distribution | 1 | 2023 | 290 | 0.220 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 299 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 151 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 381 | 0.200 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 567 | 0.200 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 4 | 0.200 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2021 | 9 | 0.200 |
Why?
|
| Civil Defense | 1 | 2021 | 11 | 0.200 |
Why?
|
| New York City | 1 | 2021 | 59 | 0.200 |
Why?
|
| Anemia, Aplastic | 1 | 2021 | 30 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 372 | 0.190 |
Why?
|
| Evidence-Based Practice | 1 | 2021 | 45 | 0.190 |
Why?
|
| Resource Allocation | 1 | 2021 | 65 | 0.190 |
Why?
|
| Hematologic Diseases | 1 | 2020 | 79 | 0.190 |
Why?
|
| Videoconferencing | 1 | 2020 | 16 | 0.180 |
Why?
|
| Triage | 1 | 2021 | 108 | 0.180 |
Why?
|
| Allografts | 1 | 2021 | 172 | 0.180 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 162 | 0.180 |
Why?
|
| Male | 5 | 2022 | 40965 | 0.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 375 | 0.180 |
Why?
|
| Infection Control | 1 | 2021 | 115 | 0.180 |
Why?
|
| Cross Infection | 1 | 2021 | 141 | 0.180 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 204 | 0.170 |
Why?
|
| Amyloidosis | 1 | 2021 | 115 | 0.170 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 166 | 0.170 |
Why?
|
| Adult | 4 | 2024 | 25648 | 0.170 |
Why?
|
| Radial Artery | 1 | 2018 | 33 | 0.170 |
Why?
|
| Leukemia | 1 | 2021 | 320 | 0.170 |
Why?
|
| Electromyography | 1 | 2018 | 183 | 0.160 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 292 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 257 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 327 | 0.160 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 115 | 0.160 |
Why?
|
| Aged | 3 | 2021 | 18415 | 0.150 |
Why?
|
| Tissue Donors | 1 | 2020 | 463 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2020 | 839 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 1195 | 0.150 |
Why?
|
| Prognosis | 2 | 2023 | 3679 | 0.140 |
Why?
|
| Thrombosis | 1 | 2018 | 296 | 0.140 |
Why?
|
| Prospective Studies | 1 | 2024 | 4213 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2024 | 8489 | 0.130 |
Why?
|
| Tympanic Membrane | 1 | 2013 | 13 | 0.120 |
Why?
|
| Facial Paralysis | 1 | 2013 | 17 | 0.120 |
Why?
|
| Ciprofloxacin | 1 | 2013 | 29 | 0.120 |
Why?
|
| Mastoid | 1 | 2013 | 17 | 0.120 |
Why?
|
| Osteomyelitis | 1 | 2013 | 54 | 0.120 |
Why?
|
| Edema | 1 | 2013 | 71 | 0.110 |
Why?
|
| Temporal Bone | 1 | 2013 | 66 | 0.110 |
Why?
|
| Young Adult | 2 | 2024 | 5976 | 0.110 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 95 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2501 | 0.100 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 194 | 0.100 |
Why?
|
| Middle Aged | 2 | 2021 | 25028 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 746 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2020 | 7993 | 0.080 |
Why?
|
| Female | 2 | 2021 | 44532 | 0.070 |
Why?
|
| Neoplasms | 1 | 2021 | 2898 | 0.070 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2601 | 0.060 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2023 | 127 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 138 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2023 | 289 | 0.050 |
Why?
|
| Remission Induction | 1 | 2022 | 722 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 589 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1313 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 2438 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 3968 | 0.030 |
Why?
|
| United States | 1 | 2024 | 6672 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 8981 | 0.020 |
Why?
|